Kornimate/medical-research-clean huggingface dataset:
psychotherapy (accelerated resolution therapy) for cancer related trauma and distress

Conditions: Hematopoietic and Lymphoid System Neoplasm; Malignant Solid Neoplasm

Summary: this trial studies whether a form of psychotherapy called accelerated resolution therapy can help with cancer distress and psychological trauma. accelerated resolution therapy is an evidence-based therapy for the treatment of depressive symptoms, trauma, and stress-related disorders. this study may provide evidence to support integration of accelerated resolution therapy into psychological treatment of cancer patients, which may decrease cancer related trauma and distress.

primary objectives: i. calculate changes, and estimate mean changes, in primary outcomes of psychological trauma and cancer distress over a six week time period while receiving weekly accelerated resolution therapy (art). ii. calculate changes, and estimate mean changes, in secondary outcomes of anxiety and depression over a six week period while receiving weekly art. iii. will use a qualitative, descriptive design to explore contextual elements of the cancer experience that are consistently distressing and/or psychologically traumatic to more fully inform a future rct testing in art in cancer distress and psychological trauma. iv. calculate changes, and estimate mean changes, in secondary outcomes of resilience and symptom distress over a six week period while receiving weekly art. outline: patients undergo art over 60-90 minutes once a week for up to 5 sessions. after completion of study intervention, patients are followed up at 1 week and again at 1 month.

Eligibility criteria:
inclusion criteria: * able to read, write and understand english * undergone chemotherapy, radiation therapy, chimeric antigen receptor t cells (car-t), or bone marrow transplant for a cancer diagnosis within the previous 3 years or have metastatic cancer * a mean score of at least 1.1 on the cancer and treatment distress (ctxd) or at least one item rated at a 3 (often true) or 4 (nearly all the time) * a minimum score of 3 on the primary care-post traumatic stress disorder screen (pc-ptsd-5) * denial of suicidal ideation or intent, with no evidence of psychotic behavior * participants must be willing and able to utilize secure web conferencing software, phone calls, or to travel to mayo clinic outside of normally scheduled visits to participate in the study
use of augmented intelligence for the interpretation of bone standard x-rays prescribed by the emergency department (immediat urgences)

Conditions: Bone Fracture

Summary: the study evaluates, in 3 emergency departments (ed) and on randomized alternate periods, the use of smarturgences®, augmented intelligence (ai) software to help the interpretation of bone standard x-rays prescibed by the ed.

"the study evaluates, in 3 emergency departments (ed) and on randomized alternate periods, the use of smarturgences®, augmented intelligence (ai) software to help the interpretation of bone radiographs prescibed by the ed. the primary objective of the organizational study is to evaluate, compared to the current organization for the interpretation of standard bone radiographs requested by the ed, the impact of an organization incorporating the milvue solution, on the reduction of the patient diagnostic error rate. a cost-consequence study is carried out, comparing from the point of view of the community (production costs according to the has recommendations), the radiological diagnosis within the framework of an organization with the milvue solution, to that within the framework of the current organization without the use of the milvue solution. the economic study will follow the scheme of the organizational study, comparing the periods with and without the milvue solution and analyzing the costs and consequences, by period and by patient. this is an open-label randomized cluster multiple period cross-over study with 6 alternate periods (3 with ai, 3 with usual organization) of 1 month in each ed. the choice of the intervention for the first period will be randomized."

Eligibility criteria:
inclusion criteria: 1. all adult referred by the ed for a conventional x-rays of all or part of the appendicular skeleton and/or pelvis and/or costal gril 2. not opposed to participate"
evaluation research of the nutrition interventions in the inhp ii areas of care india

Conditions: Underweight; Stunting; Wasting; Anemia

Summary: this study is designed to evaluate the effectiveness of care india's integrated nutrition and health program (inhp ii) to reduce malnutrition among children 0-23 months of age.


Eligibility criteria:
inclusion criteria: * mothers with a child 0-23 months of age * children 0-23 months of age * currently pregnant women * resides in the program or control area exclusion criteria: -

Keywords: malnutrition anemia infants children india
a study to evaluate the efficacy and safety of jyp0061 in patients with acute neuromyelitis spectrum disease (nmosd)

Conditions: Neuromyelitis Optica Spectrum Disorders

Summary: the goal of this clinical trial is to evaluate the efficacy and safety, of jyp0061 in acute nmosd patients. the main questions it aims to answer are: efficacy and safety of jyp0061 in acute nmosd patients. participants will be treated with low-dose jyp0061 in combination with reduced dose glucocorticoids or standard dose glucocorticoids or high-dose jyp0061. efficacy and safety evaluations will be conducted according to the protocol.

this study will be an open-label, multicenter phase 2 clinical trial. after being informed about the study and potential risks, all subjects giving written informed consent will undergo a 2-week screening period to determine eligibility for study entry. and then subjects will be treated with low-dose jyp0061 in combination with reduced dose glucocorticoids or standard dose glucocorticoids. the efficacy and safety measures will be conducted according to the protocol. if jyp0061 is effective and safe for acute nmosd patients, then subjects will be treated with high-dose jyp0061 or standard dose glucocorticoid. the efficacy and safety measures will be conducted according to the protocol.

Eligibility criteria:
inclusion criteria: * neuromyelitis spectrum disease (nmosd) patients according to 2015 international consensus diagnostic criteria. * positive aquaporin 4 immunoglobulin g (aqp4-igg) * patients with acute nmosd * female serum pregnancy test results were negative at the time of screening, subject (including partner) had no child-rearing plan and voluntarily adopted double contraceptive (non-oral contraceptives) within 6 months from screening to the last study drug administration, and had no sperm/egg donation plan; * have fully understood this study, voluntarily participate in the experiment, and voluntarily sign the written informed consent. exclusion criteria: * pregnant or lactating women; * suspected or clear allergy to similar ingredients or any ingredient in the study drug, or allergic constitution; * symptoms improved in the acute phase before the study drug was used; * unable to complete mri or gadolinium enhanced examination;
lymphadenectomy in nsclc with and without adjuvant therapy

Conditions: NSCLC; Lymph Node Metastases

Summary: adjuvant therapy in patients affected by nsclc is indicated in surgically treated cases of n2 disease, while the actual guidelines reported the possibility of a case-by-case decision in case of n1 involvement. on the other hand, the actual categorization of patients based on the hilar or mediastinal involvement (n1 or n2) risks to be too ineffective and straightforward for prognosis prediction and an indication of adjuvant treatments. this issue was underlined in the 8th tnm proposal for the n sub-classification, with a final proposal of different subgroups based on the number of involved stations. however, the iaslc committee noted that this proposal presented some limits due overlapping or not statistical significance among some survival curves, so the proposal was not adopted in the staging system. moreover, the committee stated that the lack of information regarding some data such as the number of the resected or the metastatic nodes might affect the results and limited other proposals. the objectives of this study are: * to evaluate the prognostic role of the kind of lymphadenectomy, the number of the resected and/or metastatic lymph nodes in surgically treated n positive patients in terms of survival. * to evaluate the indication and the role of adjuvant treatments in these patients. * to identify patients with increased risk of early recurrence or poor survival based on the lymph node involvement characteristics in particular, data will be collect in a prospective database including clinical and pathological data, kind of lymphadenectomy, number of resected nodes, number of metastatic nodes, kind and schedule of adjuvant therapy and follow-up status


Eligibility criteria:
inclusion criteria: * informed consent * age \>18 years * non-small cell lung cancer histology * anatomical lung resection (segmentectomy, lobectomy or bilobectomy, pneumonectomy) * pre-operative ct and pet evaluation * preoperative and postoperative tumour board discussion * intraoperative lymph node assessment (minimum 3 mediastinal stations harvested) * lymph node metastases exclusion criteria: * age \< 18 years * pregnancy * psychiatric disease * wedge resection * distant metastases

Keywords: thoracic surgery adjuvant therapy
study to determine if fibrin affects the ability of a wound to heal

Conditions: Effect of Test Articles on the Healing of a Wound Artificially Induced by Liquid Nitrogen Spray

Summary: the objective of this study is to evaluate the potential inhibitory effects of hp802-247 vehicle on wound closure (healing), by comparing mean days to closure of superficial (partial-thickness) thermal wounds against similar wounds treated with white petrolatum.


Eligibility criteria:
inclusion criteria: * provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the investigator, sub-investigator or other designated study staff member has explained the study procedures, risks, and contact information. * are male or female, ≥ 18 years of age, of any race. * are willing to attend all required study visits, and to comply with study procedures. * meet none of the exclusion criteria (any single exclusion criterion which is met by a potential subject will disqualify that subject from participation in this study. exclusion criteria: * have a history of dermatomyositis, systemic sclerosis, scleroderma, sjögren's syndrome, systemic lupus erythematosus, discoid lupus, ehler danlos disease, icthyosis vulgaris, vasculitis, or bleeding disorders (coagulopathies). * have any dermatologic disease which may be aggravated or provoked by the wounding procedure, such as lichen planus, psoriasis, or vitiligo. * have fitzpatrick scale skin type 6 (never sunburns, deeply pigmented). * are at risk of keloid or hypertrophic scar formation, based on personal history, family history, or brief skin exam (conducted at the screening visit to look for keloids or hypertrophic scars). * have been treated within the last three months for uncontrolled diabetes mellitus, peripheral vascular disease, vitamin c deficiency, connective tissue disorders, or any other disease process that impedes wound healing. * are taking concomitant medications at doses which are known to interfere with healing, such as non-steroidal anti-inflammatory drugs, anti-neoplastic drugs, or immunosuppressive drugs. * are using topical glycolic acid products, alpha-hydroxy acid products, retinoids, or chemical peel agents in the treatment areas. * are using systemic steroids or immunosuppressant agents, or have used these drugs within the past three months. * the principal investigator may declare any subject ineligible for a valid medical reason.

Keywords: fibrin, white petrolatum, wound healing
phase ii trial of combination therapy with s-1, irinotecan, and bevacizumab (sirb) in patients with unresectable or recurrent colorectal cancer

Conditions: Colorectal, Cancer

Summary: phase ii trial of combination therapy with s-1, irinotecan, and bevacizumab (sirb) in patients with unresectable or recurrent colorectal cancer


Eligibility criteria:
inclusion criteria: 1. histologically confirmed colorectal carcinoma with inoperable, locally advanced, or metastatic disease, not amenable to curative therapy 2. measurable disease or non-measurable but assessable disease according to the response evaluation criteria in solid tumors (recist) 3. patients with no previous treatment (radiotherapy or chemotherapy). patients who have received postoperative adjuvant chemotherapy are eligible if relapse is diagnosed more than 180 days after the end of such treatment. preoperative or postoperative irradiation (\<30 gy) for rectal cancer is possible 4. age \>20 years 5. life expectancy of at least 3 months 6. ecog ps of 0 or 1 7. adequate function of major organs as defined below: 1. hemoglobin \>9.0 g/dl 2. white blood cell count \>3,000/mm3 3. neutrophil count \>1,500/mm3 4. platelet count \>100,000/mm3 5. total bilirubin \<1.5 mg/dl 6. ast and alt \<100 u/l (\<200 u/l in patients with liver metastasis) 7. serum creatinine \<1.2 mg/dl 8. creatinine clearance estimate by the cockcroft-gault method \>50 ml/min (reduce initial dosage by one step if ≥50 but \<80 ml/min) 8. able to take capsules orally. 9. no electrocardiographic abnormalities within 28 days before enrollment that would clinically preclude the execution of the study, as judged by the investigator. 10. voluntary written informed consent. exclusion criteria: 1. serious drug hypersensitivity or a history of drug allergy 2. active double cancer 3. active infections (e.g., patients with pyrexia of 38℃ or higher) 4. history of gastrointestinal perforation, intestinal tract paralysis, or ileus within 1 year. 5. uncontrolled hypertension 6. serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart failure, renal failure, hepatic failure, or poorly controlled diabetes) 7. moderate or severe ascites or pleural effusion requiring treatment 8. watery diarrhea 9. treatment with flucytosine or atazanavir sulfate 10. metastasis to the cns 11. pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers. men who are currently attempting to conceive children. 12. severe mental disorder 13. continuous treatment with steroids 14. urine dipstick for proteinuria should be \<2+ 15. patient with a past history of thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism 16. major surgical procedure, open biopsy, or clinically significant traumatic injury within 4 weeks 17. long-term daily treatment with aspirin (\>325 mg/day) 18. history or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding 19. judged ineligible for participation in the study by the investigator for safety reasons.

Keywords: s-1, bevacizumab, irinotecan
a correlative study for predicting response and toxicity in patients receiving chemotherapy for breast cancer

Conditions: Breast Cancer

Summary: the proposed trial provides a unique opportunity in that it combines genomic, proteomic, and pharmacogenomic assessments in patients receiving the most commonly used chemotherapies for advanced breast cancer. to date no other trial has analyzed gene and protein expression at the same time points in the same patient, combined with clinical outcome. similar to previous attempts to predict response based on expression of a single gene or protein, the researchers expect that neither genomic or proteomic profiling alone will be sufficient to optimize therapy. rather, the researchers expect an iterative process that combines information gleaned from both platforms, modified to avoid toxicity based on pharmacogenomics.

outline: this is a 4 arm, multi-center study. sample collection: * core biopsy * serum * urine treatment regimens (investigator/patient discretion): * arm a: doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle * arm b: capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle * arm c: vinorelbine 25 mg/m2 days 1, 8, 15 of every 28-day cycle * arm d: gemcitabine 1000 mg/m2 days 1, 8, 15 of every 28-day cycle performance status \& organ function: performance status and organ function appropriate for chemotherapy in the opinion of the treating investigator according to good clinical practice (gcp). life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified cardiovascular: not specified pulmonary: not specified

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed adenocarcinoma of the breast with locally advanced or metastatic disease. * disease amenable to pre-treatment core or incisional biopsy with adequate tissue for histology and genomic/proteomic analysis. * measurable disease as assessed within 21 days prior to being registered for protocol therapy by recist. * planned chemotherapy with one of the following regimens: 1. doxorubicin 60 mg/m2 + cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle 2. capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle 3. vinorelbine 25 mg/m2 days 1, 8, 15 of every 28-day cycle 4. gemcitabine 1000 mg/m2 days 1, 8, 15 of every 28-day cycle exclusion criteria: * no serious uncontrolled medical or surgical condition that the investigator feels might compromise study participation. * negative pregnancy test obtained within 7 days prior to being registered for protocol therapy for women of child bearing potential. * unwillingness to use adequate contraception (or practicing complete abstinence). subjects should be advised that adequate contraception (or complete abstinence) must be continued while on treatment and for a period of 3 months after the final dose of chemotherapy. * no breast-feeding.
a study for g1b chc patients with ckd-3 treated with grazoprevir plus elbasvir

Conditions: Hepatitis C Viral; Chronic Kidney Disease stage3

Summary: the regimen using grazoprevir plus elbasvir treatment is promising in japan, because it may safely be used for the elderly patients with renal dysfunction. grazoprevir and elbasvir are metabolized in the liver and do not require dose-adjustment for patients with renal dysfunction. however, no data related to efficacy and safety of the grazoprevir plus elbasvir treatment for japanese elderly patients with renal dysfunction (egfr\<60 ml/min/1.73m2) have been reported. therefore, physicians are at a loss whether or not to treat the patients with renal dysfunction due to no evidence. the aim of this study is to investigate the improvement of serum endostatin level of japanese patients with ckd stage 3 after grazoprevir (ns3/4a protease inhibitor) plus elbasvir (ns5a replication complex inhibitor) treatment by a prospective, multicenter cohort study.


Eligibility criteria:
inclusion criteria: 1. subjects aged 20 years or older. 2. patients positive for hcv rna for over 6 months and infected with genotype 1b chronic hepatitis c, including compensated cirrhosis. 3. patients without co-infection of hepatitis b virus. 4. patients without co-infection of human immunodeficiency virus 5. patients with moderate chronic kidney disease (ckd stage 3) (egfr: 30-59 ml/min/1.73m2). a diagnosis of ckd is only confirmed if repeated egfr tests for at least 90 days. exclusion criteria: 1. patients with decompensated cirrhosis (child pugh b and c) 2. patients with albumin \<3.0 g/dl and platelets \<75,000 /μl 3. patients with autoimmune hepatitis 4. constant heavy alcohol drinkers (converted to ethanol ≥60 g/day) 5. patients who have a history of hypersensitivity to grazoprevir and elbasvir 6. patients who are pregnant females, or females who may become pregnant, or females who are breastfeeding 7. patients with heart disease that is hard to control (e.g., very recent cardiac infarction, severe heart failure, unstable arrhythmia) 8. patients who are under medication with drugs listed as contraindication in a package insert of grazoprevir plus elbasvir treatment 9. patients judged (by the physician in charge of research) to be inappropriate as subjects for the study for any other reasons.

Keywords: direct acting antivirals grazoprevir elbasvir
establishment and clinical application of breast cancer risk prediction model based on traditional chinese medicine four diagnostic instruments and ultrasound

Conditions: Breast Cancer Screening

Summary: construct a breast cancer risk prediction model based on traditional chinese medicine four diagnostic instruments and b-ultrasound images. ensure that the key evaluation indicators of the model reach a high level through clinical verification, so as to contribute to accurate clinical diagnosis and treatment decision-making.


Eligibility criteria:
inclusion criteria: 1. female patients aged between 30 and 75. 2. patients who have a mass detected by us examination, need to undergo surgery or needle biopsy, and obtain a definite pathological result. 3. patients who have obtained complete identification results of tongue, pulse, face, and constitution through the traditional chinese medicine four diagnostic instruments. exclusion criteria: - 1. patients with severe heart, liver, or kidney insufficiency, or other serious systemic diseases. 2. patients with a history of other malignant tumors. 3. cases with poor - quality b - ultrasound images. 4. cases with an unclear pathological diagnosis. 5. patients with obvious lesions on the face, in the oral cavity, or on the tongue that may affect the measurement results.